LOUISVILLE, Ky., May 22, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that Company management will participate at three upcoming investor conferences.
Live and archived webcasts of the events will be available on the “Event & Presentations” section of the BrightSpring investor relations website at https://ir.brightspringhealth.com/.
About BrightSpring Health Services
BrightSpring Health Services is the parent company of leading service lines that provide integrated home- and community-based pharmacy and health solutions for complex populations in need of specialized and/or chronic care. Through the company’s service lines, including pharmacy, primary care and home health care, and rehabilitation and behavioral health, we provide comprehensive care and clinical solutions in all 50 states to over 400,000 customers, clients and patients daily. For more information, visit www.brightspringhealth.com.
Contact
Investor Relations:
David Deuchler, CFA
Gilmartin Group LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Leigh White
This email address is being protected from spambots. You need JavaScript enabled to view it.
502.630.7412
| Last Trade: | US$16.81 |
| Daily Change: | 1.85 12.37 |
| Daily Volume: | 1,243,558 |
| Market Cap: | US$2.880B |
November 01, 2024 September 03, 2024 August 02, 2024 May 20, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
